Infantile FSHD is the name given to FSHD that manifests early in life when weakness is evident in childhood or infancy. This is also called early onset FSHD or paediatric FSHD. Infantile FSHD is a much rarer condition than the adult onset FSHD.
Infantile FSHD tends to be more severe compared to the adult condition. Many children with the condition experience a faster and more severe decline in muscle function. Hearing and sight complications are also more prevalent.
While much is known about the adult form of FSHD the infantile form is less well known. FSHD Global supports a multinational trial into infantile FSHD being conducted through the cooperative international neuromuscular research group. This trial is characterising infantile FSHD and following a group of children through time in order to better understand how and why the infant form of FHSD differs from the adult form. The trial is also identifying potential targets for drug discovery. For more information on the results of this trial please see our page dedicated to this study.
At the moment we don’t know why infantile FSHD is more severe than adult onset. It appears that many children with FSHD have larger deletions of D4Z4 repeats which is associated with more severe symptoms in adults. Emerging research also suggests that there may be multiple mutations working in synergy making the symptoms and progression more severe.
FSHD Global has also launched the Monica Ellis Children’s Medical Research grant. The purpose of this grant is to fund basic, therapeutic and diagnostic research into infantile FSHD. It is our hope that through this grant and the research that is currently underway around the world our understanding of this severe and debilitating form of FSHD will improve exponentially. This will pave the way for new treatments and even a cure.
FSHD Global will continue to update this page as new discoveries are made. If you woild like to kept informed of new research in the area of infantile FSHD please subscribe to our monthly newsletter